Sept. 21 Quick Takes: venture funding for Novellus, Immune Regulation, XWPharma and CoreMap

Novellus’ $57M series C to fund development of BRAF inhibitor
Novellus Ltd. raised $57 million to support development of lead program PLX-8394, a BRAF inhibitor that the Israeli biotech licensed from Daiichi Sankyo Co. Ltd. (Tokyo:4568) subsidiary Plexxikon this year. Novellus is developing PLX-8394 in clinical settings that lack approved BRAF inhibitors, including BRAF fusions and certain BRAF-mutated gliomas. 

Immune Regulation raises $53.4M B round
Immune Regulation Ltd. (formerly Peptinnovate Ltd.) raised £40.6 million ($53.4 million) in a series B round led by Morningside Ventures to support multiple Phase II trials of its two lead assets designed to reset the immune system in patients with autoimmune or allergic diseases...